XSOLLA
7.8.2024 15:39:31 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, will attend and present at the Devcom Developer Conference and Gamescom 2024, the world's largest computer and video games event, taking place from August 19th to August 23rd in Cologne, Germany, EU. These events will provide the ideal platform for Xsolla to showcase its cutting-edge solutions, designed to create seamless Cross-Play and Cross-Pay experiences for game developers and players. Their powerful new offerings include Xsolla Backend, Xsolla Mobile SDK, and Xsolla Instant Solutions, featuring Instant Web Shop, Instant Game Sales, Instant Launcher, and Instant Cloud Gaming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807882430/en/
(Graphic: Xsolla)
Xsolla Backend
Xsolla Backend offers developers a scalable and affordable solution to enhance game functionality and player engagement across all technology platforms. This includes a built-in launcher and website, efficient matchmaking, over 20 game management systems, and robust cross-play and multiplayer functionalities.
Xsolla Mobile SDK
Xsolla's Mobile SDK is designed to enhance revenue streams for mobile game developers by enabling seamless in-game payments and supporting out-of-store builds and in-store processing for in-app purchases (IAP). With compatibility across platforms like AltStore and Epic Games Store Mobile, the SDK also empowers developers to offer a modern payment experience that complies with iOS and Android regulations. It provides global coverage with over 700 payment methods, making it easier than ever for developers to monetize their games and reach a wider audience.
Xsolla Instant Solutions
Xsolla expanded the Instant Web Shop to include offers of Instant Game Sales, Instant Launcher, and Instant Cloud Gaming to enable faster integration and revenue generation for video game developers. Instant Web Shop enables quick setup of online stores with features like personalization and promotions to enhance user engagement and revenue. Instant Game Sales facilitates direct-to-consumer sales by importing content from platforms like Steam and Epic Game Store. Instant Launcher provides a pre-designed app for direct game distribution, supporting various release stages while reducing costs and promoting cross-engagement. Instant Cloud Gaming allows developers to launch a branded cloud gaming platform quickly, offering pre-launch testing and global reach to expand revenue opportunities.
“We’re excited to be back at Gamescom this year and showcase our latest solutions to the global gaming community,” said David Stelzer, President of Xsolla. “Our solutions are crafted to empower developers and publishers with the tools they need to succeed in today’s dynamic landscape. We invite all attendees to visit our booth and see firsthand how Xsolla can elevate their game development and business operations.”
Attendees can visit Xsolla at Hall 2.2, Booth #A-030 B-037, where live demonstrations of Xsolla’s Payments and Web Shop and these latest solution releases will be held throughout the event. Xsolla’s team of experts will be available to answer questions, provide insights, and discuss how these tools can be tailored to meet the unique needs of each developer and publisher.
For more information, connect and book meetings with Xsolla at the Devcom Developer Conference and Gamescom 2024, visit xsolla.events/gamescom24
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807882430/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom